#USA #San Diego #Alzheimer’s Disease #Circular Genomics #Dr. Henrik Zetterberg

Circular Genomics Expands Its Scientific Advisory Board

Circular Genomics, a pioneering biotechnology company focused on using brain-derived circular RNA biomarkers, has recently appointed Dr. Henrik Zetterberg, a distinguished expert in neurochemistry and a leading figure in Alzheimer's disease research, to its Scientific Advisory Board. This strategic move aims to bolster the company's efforts in advancing precision medicine for neurodegenerative diseases and highlights the organization’s commitment to improving diagnostic tools in this critical area.

Dr. Zetterberg brings a wealth of knowledge and expertise to Circular Genomics. Currently, he serves as a Professor of Neurochemistry at the University of Gothenburg in Sweden, as well as at the University of Wisconsin-Madison and University College London (UCL) in the UK. As a prominent researcher, he has made substantial contributions to the understanding and development of blood-based biomarkers for Alzheimer’s disease and other neurodegenerative conditions.

His groundbreaking work is well recognized, placing him at the forefront of Alzheimer's disease diagnostics. Notably, Dr. Zetterberg leads the UK Dementia Research Institute Fluid Biomarker Laboratory at UCL and heads the Department of Psychiatry and Neurochemistry at the University of Gothenburg. His significant research efforts have resulted in the establishment of non-invasive biomarkers, including neurofilament light chain (NfL), phosphorylated tau (p-tau 217), GFAP, and amyloid-beta, which are instrumental in detecting and staging Alzheimer’s disease and other neurodegenerative disorders.

Recently, Dr. Zetterberg’s insights have played an essential role in shaping the scientific and clinical frameworks for blood-based diagnostics, showcased by his numerous high-impact publications and engagements at major neuroscience conferences worldwide. His position at Circular Genomics aligns seamlessly with the company's mission to transform how brain disorders are understood, diagnosed, and treated through innovative circRNA biomarker technologies.

Dr. Zetterberg is excited about his new role, noting, “Circular RNAs represent a fundamentally new class of brain-derived biomarkers that can provide a comprehensive view of brain biology. The potential to advance precision medicine in Alzheimer’s disease and related disorders is tremendous. I am eager to apply my expertise in biomarker validation and clinical translation to assist in making these advanced diagnostics accessible to patients.”

Circular Genomics’ Chief Scientific Officer and Co-founder, Dr. Nikolaos Mellios, expressed confidence in the addition of Dr. Zetterberg to the team, stating, “We are privileged to welcome Dr. Zetterberg to our Scientific Advisory Board. His unparalleled expertise is invaluable to us as we continue enhancing our circRNA platform.” Dr. Mellios emphasized that Dr. Zetterberg’s guidance is crucial for ensuring that the company’s Alzheimer’s diagnostics meet the highest scientific standards while effectively addressing the needs of patients and their families.

The company currently focuses on developing circRNA blood-based diagnostic assays to identify Alzheimer’s disease and predict risk, collaborating with esteemed institutions such as Washington University in St. Louis. Circular Genomics has recently finalized exclusive IP licenses with globally recognized research organizations, further solidifying its role as a leader in the arena of Alzheimer’s diagnostic innovations.

In summary, Circular Genomics is committed to revolutionizing neuropathology through its proprietary technology and collaborations with experts like Dr. Zetterberg. With this notable addition to their advisory board, the company emphasizes its dedication to creating transformative and precise medical solutions for Alzheimer’s disease and other neurodegenerative conditions, making strides toward a future where brain disorders can be comprehensively measured and managed.

For more information about Circular Genomics and its groundbreaking research, visit www.circulargenomics.com.